Skip to Content
Merck

36-012

Anti-nitro-α/β-Synuclein (Tyr39) Antibody, clone nSyn14

clone nSyn14, Upstate®, from mouse

Synonym(s):

Anti-NACP, Anti-PARK4, Anti-PD1

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Anti-nitro-α/β-Synuclein (Tyr39) Antibody, clone nSyn14, clone nSyn14, Upstate®, from mouse

biological source

mouse

antibody form

ascites fluid

antibody product type

primary antibodies

clone

nSyn14, monoclonal

species reactivity

human

manufacturer/tradename

Upstate®

technique(s)

immunohistochemistry: suitable
western blot: suitable

NCBI accession no.

NM_000345.2
NM_007308.1

UniProt accession no.

P37840
Q16143

shipped in

dry ice

target post-translational modification

nitration (Tyr39)

Quality Level

100

Gene Information

human ... SNCA(6622)

Analysis Note

routinely evaluated by immunoblot on recombinant protein nitrated in vitro

Application

Anti-nitro-α/β-Synuclein (Tyr39) Antibody, clone nSyn14 detects level of nitro-α/β-Synuclein (Tyr39) & has been published & validated for use in WB, IH.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases

Biochem/physiol Actions

α- or β-synuclein nitrated at Tyr39

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

α-Synuclein, Mr 14.5kDa
β-Synuclein, Mr 17kDa

Immunogen

full-length recombinant human α-Synuclein nitrated in vitro

Physical form

Ascites
Format: Purified
ascites with 0.05% sodium azide

Preparation Note

2 years at -20°C

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

10 - Combustible liquids

wgk

WGK 1

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hugo Vicente Miranda et al.
Scientific reports, 7(1), 13713-13713 (2017-10-24)
Parkinson's disease (PD) is a progressive neurodegenerative disorder known for the typical motor features associated. Pathologically, it is characterized by the intracellular accumulation of alpha-synuclein (aSyn) in Lewy bodies and Lewy neurites. Currently, there are no established biochemical markers for
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases
Duda, J. E., et al
Annals of Neurology, 52, 205-210 (2002)
J M Souza et al.
The Journal of biological chemistry, 275(24), 18344-18349 (2000-04-05)
Intracellular proteinaceous aggregates are hallmarks of many common neurodegenerative disorders, and recent studies have shown that alpha-synuclein is a major component of several pathological intracellular inclusions, including Lewy bodies in Parkinson's disease (PD) and glial cell inclusions in multiple system
Emilio Fernández et al.
Antioxidants & redox signaling, 21(15), 2143-2148 (2014-08-16)
The research group has detected nitrosative stress and a singular version of nitrosylated serum α-synuclein in serum of Parkinson's disease (PD) patients. Dysfunction of the thyroid gland has been proposed to be linked to this disease. The aim of the
Pedro Magalhães et al.
NPJ Parkinson's disease, 8(1), 93-93 (2022-07-23)
Parkinson's disease (PD), the second most common progressive neurodegenerative disease, develops and progresses for 10-15 years before the clinical diagnostic symptoms of the disease are manifested. Furthermore, several aspects of PD pathology overlap with other neurodegenerative diseases (NDDs) linked to
View All Related Papers

Global Trade Item Number

SKUGTIN
36-01204053252331893

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service